Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing Residual Albuminuria in Japanese Subjects with Diabetic Nephropathy Using Atrasentan
jRCT2080221551Phase 2
- Sponsor
- Abbott Laboratories
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atrasentan in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis and albuminuria (3 arms), sponsored by Abbott Laboratories.
02
Drugs
atrasentan
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosisalbuminuria
Beyond the preview
Go deeper on jRCT2080221551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221551.